Conditions: Triple Negative Breast Neoplasms
Keywords: PF-03084014 Notch Alterations
Enrollment: 19
Healthy volunteers: no

Brief summary:
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)

Detailed description:

Arms:
arm 1: PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.

Interventions: intervention 1: PF-03084014 intervention 2: PF-03084014 intervention 3: PF-03084014
Intervention descriptions: intervention 1: Tablet, 10 mg, twice a day. intervention 2: Tablet, 50 mg, twice a day intervention 3: Tablet, 100 mg, twice a day

Protocol document: